What is the role of platinum agents in the treatment of metastatic breast cancer in patients with BRCA mutations?
2 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
The TNT study compared taxanes versus carboplatin in triple negative breast cancer and did not show a difference in response rate. However, amongst BRCA germline mutation carriers there was a significantly higher response rate amongst women with BRCA mutations. Therefore, platinums are good options ...